Aurobindo Pharma Sangareddy facility gets 10 USFDA observations

Hyderabad: Drugmaker Aurobindo Pharma has recently announced that the United States Food and Drug Administration (USFDA) has concluded an inspection with 10 observations at the Company's Unit - IX, an intermediate facility situated at Gundlamachnoor Village, Sangareddy District, Telangana.

The facility was inspected from November 10 to November 18, 2022.

Read also: USFDA issues EIR for Aurobindo Pharma Andhra Pradesh facility

Aurobindo Pharma Limited is a global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients globally in over 155 countries.

The company has 27 manufacturing and packaging facilities that are approved by leading regulatory agencies, including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA. The company's product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics, and Anti-Allergic.

Read also: Aurobindo Pharma subsidiary's plant gets one observation from USFDA